Zürich Switzerland 2nd of October 2019 – HypoPet AG reported today that it has executed a contract with a top-tier global animal health company.
HypoPet AG announced Wednesday the signing of an agreement with a major animal health company. The execution of this agreement is another important step in the companies publicly stated business plan, which is to form strategic alliances with leading global companies to advance its technology, projects and pipeline. It is the third deal in the increasingly lucrative animal health sector announced by HypoPet since its founding. The others being license deals for their HypoCat vaccine for cat allergy suffered by humans and a therapeutic vaccine for treating canine atopic dermatitis.
Dr Gary T Jennings, CEO of HypoPet AG commented, “We are extremely pleased to have signed this agreement with a leading animal health company and are looking forward to the collaboration and accessing their formidable research and development capabilities. We appreciate the innovative spirit and foresight of our new partner and view this agreement as further endorsement of the potential of our technology and the quality of the science performed by our R&D team”.
For further information, please contact
HypoPet AG Moussonstrasse 2 CH-8044 Zürich, Switzerland
Gary Jennings, PhD